Adrenergic Drug Market Size & Share, by Drug Class (Vasopressors, Bronchodilators, Catecholamine); Route of Administration (Intravenous Route, Oral Route, Inhalation); Disease Indication (Bronchitis, Cardiac Arrest, Shock, Chronic Obstructive Pulmonary Disease); Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-Commerce) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 2541
  • Published Date: Nov 24, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Adrenergic Drug Market size is expected to reach USD 9 billion by the end of 2036, expanding around 6% CAGR during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of adrenergic drug was over USD 3 billion. The growth of this sector is poised to be encouraged by a surge in number of cases of COVID-19. For instance, worldwide coronavirus (COVID-19) incidence were almost 767 million as of June 13, 2023. Hence, the market demand for adrenergic drug is set to increase.

Adrenergic drug has been increasingly used for the treatment of patients suffering from different allergic reactions such as food allergies. According to the Food and Agriculture Organization of the United Nations, nearly 220 million people across the globe have food allergies.


Adrenergic Drug Market Overview
Get more information on this report: Request Free Sample PDF

Adrenergic Drug Market: Growth Drivers and Challenges

Growth Drivers

  • Surge in Prevalence of Cardiovascular Disease- According to the World Health Organization, on a worldwide scale cardiovascular diseases (CVDs) account for 17.9 million deaths every year, putting them as the leading cause of death. As a result, the demand for the adrenergic drug market is estimated to rise. An essential category of adrenergic drug referred to as beta-adrenergic blockers (β-blockers) is utilized for treating a variety of heart conditions, such as hypertension, angina pectoris, arrhythmias, thicker heart muscle (hypertrophic cardiomyopathy), and heart failure, which is caused by a reduced heart's ability to pump blood to the heart muscle and an irregular heartbeat. It has been confirmed that β-blockers lower the chance of dying from a heart attack or having another one in those who have already had one.
  • Rising Geriatric Population- The organs in your body age as well as people do. Numerous medical problems arise in old age as a result of this. About 76% of senior citizens have two or more chronic diseases, and nearly 91% have at least one. The cardiovascular system and blood vessels can alter with age, raising the risk of heart disease. Additionally, mental health deteriorates with age, precisely as physical health does. This indicates that at least one mental health disorder affects over 14% of those over the age of 60. Alzheimer's disease, sadness, and anxiety are prevalent among the elderly population. Therefore, the adrenergic drug market revenue is set to rise.
  • Growing Research & Development for the Launch of New Products- The pharmaceutical business all around the world creates various adrenergic medications each year that offer significant medicinal advantages. The risk for novel diseases emerging was recently brought to light by the COVID-19 pandemic. Both the treatment of emerging disease symptoms and immunization against the spread of emerging diseases necessitate the development of novel medications. Drugs that address the causes or symptoms of illnesses that have long been known about however were previously incurable can be developed when additional information is researched about the pathophysiology and metabolism of diseases. As a result, there has been surge in research & development activities for the launch of new medications.

Challenges

  • Side Effects of Adrenergic Drug - Variations in blood pressure and heart rate are among the most frequent side effects. Common side effects of selective binding to beta-1 receptors include hypertension, palpitations, and tachycardia. Anxiety and tachyarrhythmias can also be prevalent. Excessive dosages might cause harmful arrhythmias. Additionally, furthermore, caution has been advised while giving beta-2 agonists since patients ought to be watched for effects on the central nervous system, blood pressure, heart rate, and paradoxical bronchospasm. Additionally, angioedema, atrioventricular (AV) block, and hypersensitivity can happen when alpha-2 agonists are prescribed. Among the possible side effects of beta-1 agonists include tremors, migraines, and vomiting. Hence, the adrenergic drug market revenue is predicted to be restricted over the forecast period.
  • Lack of Approval for Adrenergic Drug by FDA
  • High Price of Adrenergic Drug

Adrenergic Drug Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~ 6%

Base Year Market Size (2023)

~ USD 3 Billion

Forecast Year Market Size (2036)

~ USD 9 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Adrenergic Drug Segmentation

Drug Class (Vasopressors, Bronchodilators, Catecholamine)

Adrenergic drug market from the bronchodilators segment is predicted to hold 50% of the revenue share during the forecast period. As a class of drug, bronchodilators promote breathing by expanding the bronchi and relaxing the muscles in the lungs. They're frequently employed to treat long-term illnesses including asthma, a common lung ailment brought on by inflammation of the airways, where the airways may become narrowed and inflammatory. Hence, with the growing prevalence of asthma the segment is set to experience the highest growth. Over 300 million people globally are affected by asthma, which has a significant morbidity and mortality rate. Additionally, individuals with asthma are more inclined to suffer from atopic dermatitis (eczema) or allergic rhinitis (hay fever). Hence, the demand for bronchodilators is growing.

Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-Commerce)

The hospital segment is projected to account for 60% share of the global adrenergic drug market during the forecast period. Adrenergic drug is usually prescribed by doctors in the hospital and additionally, in some cases the patients are kept under observation after the consumption of this drug. Hence, most people prefer hospitals for the distribution for this drug. Furthermore, most of the medications are made available only in the hospital pharmacy. Hence, consumers might be entangled to purchase the same from there. Also, the price of various medications is hospitals especially the government is relatively low.

Our in-depth analysis of the global adrenergic drug market includes the following segments:

          Drug Class

  • Vasopressors
  • Bronchodilators
  • Catecholamine

          Route of Administration

  • Intravenous Route
  • Oral Route
  • Inhalation

          Disease Indication

  • Bronchitis
  • Cardiac Arrest
  • Shock
  • Chronic Obstructive Pulmonary Disease

          Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • E-Commerce

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Adrenergic Drug Industry - Regional Synopsis

North American Market Forecast

The North America adrenergic drug market is poised to rise by generating the highest share of about 35% over the forecast period. The major factor to encourage this growth is the rising prevalence of chronic disease. Nearly half of all Americans, or about 132 million people, are believed to suffer from a minimum of one chronic ailment, such as arthritis, heart disease, or hypertension. That number is projected to rise to over 169 million by 2030, which is about 14 million more than it was even ten years ago. Moreover, this region is considered to be the most active for various launches of medication since they have the highest spending on pharmaceuticals. Also, there has been an upsurge in patient population in this region and hence this region might also be held responsible for the spending on launch medication. Hence, the demand for market in this region is expanding.

APAC Market Analysis

The adrenergic drug market in Asia Pacific is also expected to experience the significant growth over the forecast period. This growth is set to be influenced by the growth in the prevalence of COPD. Despite being a condition that can potentially be prevented and treated, chronic obstructive pulmonary disease (COPD) is associated with high morbidity and mortality, resulting in a significant social and economic burden. The Epidemiology and Impact of COPD (EPIC) Asia population-based survey results indicate a high incidence of COPD in the participating Asia-Pacific territories and a significant socioeconomic burden of the disease in this region. As a result, the importance for adrenergic drug is rising in order to cure and this disease. Additionally, there has been surge in awareness regarding cardiovascular disease in Asia Pacific and the medication available for this. Hence, this is also projected to encourage the adrenergic drug market growth in this region.

Research Nester
Adrenergic Drug Market Region
Get more information on this report: Request Free Sample PDF

Companies Dominating the Adrenergic Drug Market

top-features-companies
    • Pfizer, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis AG
    • GSK plc.
    • AstraZeneca
    • Merck & Co., Inc.
    • Sanofi
    • Johnson & Johnson, Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Viatris Inc.

In-the-news

In The News

  • January 11, 2023: The FDA has authorized Airsupra, an inhalation aerosol containing albuterol and budesonide, for the treatment or prevention of bronchoconstriction as needed, as well as to lower the risk of asthma attacks in individuals with asthma who are 18 years of age or older. The medication known as Airsupra is a combination of the beta-2 adrenergic agonist albuterol and the corticosteroid budesonide. It is the first short-acting beta-agonist and inhaled corticosteroid (ICS) combo to be approved in the United States. Furthermore, Airsupra is the first ICS-containing medicine approved in the United States for use as an asthma relief (as opposed to a controller).
  • September 27, 2023: Global healthcare leader Viatris Inc. and clinical-stage ophthalmic biopharmaceutical company Ocuphire Pharma, Inc., which develops and markets small-molecule therapies for the treatment of retinal and refractive eye disorders, announced that the FDA in the United States has approved RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis caused by parasympatholytic (like tropicamide) or adrenergic agonists (like phenylephrine).  

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 2541
  • Published Date: Nov 24, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are surge in prevalence of cardiovascular disease, rising geriatric population, and growing research & development for the launch of new products.

The market size of adrenergic drug is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2024-2036.

The major players in the market are Pfizer, Inc., Novartis AG, GSK plc., AstraZeneca, and others.

The bronchodilators segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Adrenergic Drug Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying